| Source: |
| Type: oncogene |
| The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells. -C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A Inhibitors (downregulate): Curcumin Resveratrol: downregulate c-Myc expression. Epigallocatechin Gallate (EGCG) Quercetin Berberine: decrease c-Myc expression and repress its transcriptional activity. |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
| 3095- | RES, | Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk |
| - | in-vitro, | BC, | NA |
| 4657- | RES, | Resveratrol, cancer and cancer stem cells: A review on past to future |
| - | Review, | Var, | NA |
| 4666- | RES, | Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway |
| - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Lung, | A549 |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 1140- | SIL, | Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |
| - | in-vitro, | PC, | AsPC-1 | - | in-vivo, | PC, | NA | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 2234- | SK, | Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1 |
| - | in-vitro, | GC, | NA |
| 5331- | TFdiG, | Anti-Cancer Properties of Theaflavins |
| - | Review, | Var, | NA |
| 5222- | TQ, | Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB |
| - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 2097- | TQ, | Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2095- | TQ, | Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis |
| - | Review, | Var, | NA |
| 2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
| - | Review, | Var, | NA |
| 3413- | TQ, | Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase |
| - | in-vitro, | CRC, | HCT116 |
| 3411- | TQ, | Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone |
| - | Review, | Var, | NA |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 2454- | Trip, | Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ |
| - | in-vitro, | HNSCC, | HaCaT | - | in-vivo, | NA, | NA |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 942- | UA, | Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling |
| - | vitro+vivo, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4837- | Uro, | Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review |
| - | Review, | Var, | NA |
| 3136- | VitC, | Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer |
| - | in-vitro, | Colon, | SW48 | - | in-vitro, | Colon, | LoVo |
| 1817- | VitK2, | Research progress on the anticancer effects of vitamin K2 |
| - | Review, | Var, | NA |
| 1214- | VitK2, | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
| 2425- | γ-Toc, | Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis |
| - | in-vitro, | NA, | MCF-7 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:35 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid